UNSPSC 51342711: Interferon gamma-1b

This classification denotes an interferon, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21K6M2I7AG. European Medicines Agency schedules Interferon alfa-n1 in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12076MIG. As of Q4 2014, INTERFERON GAMMA-1B remains the US FDA Preferred Term for this commodity. Interferon gamma-1b bears US NLM identifiers UMLS ID C1579322 and NCI Concept Code C100089. SMILES: NONE.

UNSPSC 51342711 Interferon gamma-1b is a Commodity code that nominally designates a specific immunological therapeutic agent, yet the recent state and local opportunities tagged under this code do not reflect procurement of interferon gamma-1b itself. Instead, the opportunities show state and local buyers soliciting naloxone, drug deactivation systems, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing vehicles. The mismatch between the code's narrow pharmaceutical designation and the breadth of health-supply procurement tagged to it suggests either systematic miscoding in state and local procurement systems or a data artifact that does not reflect genuine interferon gamma-1b demand at the state and local level. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local members across multiple jurisdictions including Oregon).

Geographic activity appears concentrated in Florida, Texas, Minnesota, and Oregon based on the recent opportunities. Seminole County, Florida released an IFB for naloxone and drug deactivation systems (IFB60459723LAS) with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually; the City of Tampa issued an ITB for medical and first aid supplies (26P00145) with a March 13, 2026 deadline, an estimated contract value of $700,000, and a Small Local Business Enterprise set-aside with a 5 percent bid discount; the Texas Health and Human Services Commission posted an RFI for direct-to-manufacturer prescription programs (HHS0017013) with an April 3, 2026 response deadline; and the Minnesota Department of Administration, on behalf of MMCAP, released an RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802) with a March 26, 2026 deadline. The code shows little activity genuinely aligned with interferon gamma-1b procurement under its stated scope.